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1. Abbreviations 
 
µg   micrograms 
µL   microliters 
µm   micrometer 
AML                        acute myeloid leukemia  
BM   bone marrow 
BMCM  bone marrow culture medium 
BSA   bovine serum albumin 
Bala   balanced 
CD150neg  HCS that were sorted for CD150- 
CD150neg/HoxA9 HCS that were sorted for CD150- and transduced with a 
retroviral vector that overexpresses HoxA9 
CD150pos  HCS that were sorted for CD150+ 
CD150pos/HoxA9 HCS that were sorted for CD150+ and transduced with a 
retroviral vector that overexpresses HoxA9 
HSC   hematopoetic stem cell 
FAB   French-American-British 
Fig   Figure 
FACS   Fluorescence activated flow cytometry 
HOX   homeobox gene 
dH2O   double distilled water 
DMEM  Dulbecco's modified Eagle's medium 
E. coli   Escherichia coli 
EDTA   ethylenediaminetetraacetic acid 
GFP   green fluorescent protein 
et al.(lat.)  et alii; and others 
g   gram 
LB medium  lysogeny broth medium 
Ly-bi   lymphoid-biased 
mAb   monoclonal antibody 
mg   milligram 
min   minute 
	   2	  
mL   milliliter 
mM   millimolar 
My-bi   myeloid-biased 
ng   nanogram 
PBS   phosphate buffered saline 
pH  negative decimal logarithm of the hydrogen ion activity in a 
solution 
PI   propidium iodide 
RCF(g)  relative centrifugal force or g-force 
SD   standard deviation 
vs.   versus 
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2. Abstract 
2.1 Abstract in English 
Introduction: The hematopoietic stem cell (HCS) compartment does not represent a 
homogenous group of cells but instead consists of 3 subsets termed myeloid-biased 
(My-bi), lymphoid-biased (Ly-bi), and balanced (Bala) HSCs. Each of these possess 
a distinct pre-programmed proliferation and differentiation behavior, which helps us to 
determine if only 1 of these subsets contains cells that induce acute myeloid 
leukemia (AML). 
 
Method: Highly purified HSCs were separated into 2 different subsets Ly-bi (CD150-) 
and My-bi (CD150+) using fluorescence-activated cell sorting. The sorted cells were  
transduced with a retroviral vector expressing HoxA9, a gene known to induce AML, 
and injected into mice (primary hosts). Blood samples were taken regularly and 
analyzed in terms of leukemic behavior. After euthanizing the mice, spleen and bone 
marrow were analyzed, and whole bone marrow cells from these mice were serially 
transplanted into naive mice (secondary hosts). In line with the previous experiments, 
the leukemic behavior was again examined using blood analysis. Finally, whole bone 
marrow and spleen from these secondary hosts was transplanted into new tertiary 
hosts, and the time of survival of these mice was determined. 
  
Results: Mice injected with Ly-bi HSCs expressing HoxA9 displayed a shift of 
differentiation towards the myeloid lineage and a high percentage of Mac-1 positive 
cells, which is typical for AML. Additionally, typical signs of leukemia were observed 
in 70% of the primary hosts, which was characterized by an enlarged spleen. After 
serial transplantation, the development of leukemia became more aggressive as 
indicated by increased spleen weight and the loss of blood cell markers. The tertiary 
host mice died within 4 weeks of transplantation. In contrast, mice injected with My-bi 
HSCs expressing HoxA9 showed no signs of leukemia in primary host mice and 
lower levels of HoxA9 expression in bone marrow and spleen. Transduced cells did 
not differentiate towards the myeloid lineage and did not behave like those of AML. 
Only after bone marrow serial transplantation were differentiation shifts towards the 
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myeloid lineage and enlarged spleens observed in these mice. Strikingly, the tertiary 
host mice survived up to 5 months.  
 
Conclusion: Important variations in the onset of primary AML and survival were 
observed between mice that received Ly-bi and My-bi HSCs when overexpressing 
HoxA9. Mice that received the transduced subset Ly-bi showed an early onset and a 
fulminant progress of AML. In contrast to this, mice injected with My-bi HSCs showed 
a more gradual onset of disease and a longer time of survival. 
 
2.2 Abstract in German 
Einleitung: Das hämatopoetische Stammzellenkompartiment besteht nicht, wie 
lange angenommen, aus einer homogenen Masse, sondern aus drei verschieden 
Stammzelluntergruppen: myeloid-biased (My-bi), lymphoid-biased (Ly-bi) und 
balanced (Bala). Aus dieser Erkenntnis ergeben sich neue Fragestellungen und 
Antwortmöglichkeiten. In dieser Arbeit wird die Frage behandelt, ob nur eine dieser 
Untergruppen die Zellen enthält, die eine Akute Myeloische Leukämie (AML) 
auslösen. 
 
Methodik: Zunächst wurden hochreine hämatopoetische Stammzellen in My-bi 
Stammzellen (CD150+) und Ly-bi Stammzellen (CD150-) unterteilt. Die sortierten 
Zellen wurden anschließend mit einem HoxA9-exprimierenden retroviralen Vektor 
(einem AML auslösenden Gen) transduziert und in Mäuse (primäres Wirtstier) 
injiziert. Bei regelmäßigen Blutkontrollen wurden diese auf leukämisches Verhalten 
überprüft. Nach dem Töten der Mäuse wurden die Milz und das Knochenmark 
untersucht, zusätzlich wurden Knochenmarkszellen in neue Mäuse (sekundäres 
Wirtstier) transplantiert. Bei diesen Mäusen wurde, wie beim ersten Experiment, das 
leukämische Verhalten mit Hilfe von Bluttests kontrolliert. Schließlich wurden Milz- 
und Knochenmarkszellen dieser Mäuse in tertiäre Wirtstiere transplantiert und es 
wurde die Überlebenszeit bestimmt. 
 
Ergebnisse: Mäuse, die HoxA9-überproduzierende Ly-bi Stammzellen erhalten 
haben, zeigten eine Verschiebung der Differenzierung hin zur myeloischen Reihe 
und eine große Anzahl Mac-1-positiver Zellen in Blut, Milz und Knochenmark. Dieses 
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Verhalten ist typisch für die AML. Des Weiteren zeigten 70 % der primären 
Wirtsmäuse weitere typische Anzeichen von Leukämie, unter anderem eine deutlich 
vergrößerte Milz. Nach der seriellen Transplantation von Knochenmarkszellen in die 
sekundären Wirtsmäuse wurde die Leukämie aggressiver, was durch stark 
vergrößerte Milzen und den Verlust von Blutzellmarkern erkennbar wurde. Die 
tertiären Mäuse starben alle innerhalb von 4 Wochen. Im Gegensatz dazu traten bei 
den primären Mäusen, die My-bi-Stammzellen mit HoxA9-Expression erhalten 
hatten, keinerlei Anzeichen für Leukämie auf. Zudem waren bei diesen eine 
niedrigere Expression von HoxA9 in Milz und Knochenmark festzustellen, dazu keine 
Verschiebung der Differenzierung und auch keine anderen Anzeichen für Leukämie. 
Erst nach der seriellen Transplantation von Knochenmarkszellen kam es zu einer 
Verschiebung der Differenzierung hin zur myeloischen Reihe und zu vergrößerten 
Milzen in den sekundären Wirtsmäusen. Als auffällig hat sich erwiesen, dass die 
tertiären Mäuse bis zu 5 Monate überlebten. 
 
Schlussfolgerung: Mäuse, die transduzierte Ly-bi-hämatopoetische Stammzellen 
erhalten haben, zeigten ein frühes Auftreten und einen deutlicheren Verlauf einer der 
AML beim Menschen vergleichbaren Leukämie. Auf der anderen Seite ist die 
Leukämie bei Mäusen, die transduzierte My-bi-Stammzellen erhalten haben, 
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3. Introduction 
3.1. Stem cells 
Stem cells are defined by their ability for self-renewal and for differentiation into 
different cell types. They play an essential role during embryonic development as 
well as tissue replenishment and repair. One way to classify stem cells is by their cell 
potency. Totipotent stem cells have the capability to give rise to virtually all types of 
cells in an organism, such as the zygote, which is a single cell formed from the fusion 
of an egg cell and a sperm cell. Pluripotent stem cells, like embryogenic stem cells, 
have the ability to form all cell types of the 3 germ layers - endoderm, mesoderm, 
and ectoderm. Multipotent stem cells possess the potential to differentiate into 
different cells of 1 lineage. The best-described multipotent stem cell population is the 
HSC population. Unipotent stem cells can only give rise to 1 cell type. (1-3) 
	  
3.1.1. Hematopoietic stem cells 
Alexander A. Maximow developed one of the first theories of hematopoiesis and 
HSCs at the beginning of the 20th century (4, 5). HSCs are defined by their ability to 
self-renew and to generate all cells from the myeloid and lymphoid lineage through 
cell differentiation, and they can be found in different locations during development. 
Early hematopoiesis takes place in the placenta, yolk sac, the aorta-gonad 
mesonephros region, the fetal liver, and bone marrow. In adult mammals, the subset 
of HSCs is highly limited. HSCs are mostly found in bone marrow and less frequently 
in the circulating bloodstream, and they represent the top of the hierarchical process 
of hematopoiesis. Moreover, HSCs are capable of differentiating into progenitors that 
become progressively restricted to several or single lineages (Fig. 1) (6).  
A major step in the research of HSCs was achieved in 1951, by the research teams 
of Lorenz and Jacobson, demonstrating that lethally irradiated mice managed to 
survive after receiving bone marrow tissue from donor animals (7, 8). Similar results 
were achieved by Ford et al. (9) suggesting that single bone marrow cells are 
capable of replenishing the whole blood compartment. In 1988, Spangrude et al. (10) 
managed to isolate HSCs using phenotypic markers. Since then, great effort has 
been made to improve the protocols for isolating and purifying HSCs (11, 12). 
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Obtaining highly purified HSCs is one crucial aspect of improving stem cell research. 
One of these protocols was introduced by Osawa et al. (13). They used lineage 
markers negative (Lin-), c-Kit+, Sca-1+ (LSK+), CD34- mouse bone marrow cells that 
resulted in a cell population highly enriched for HSCs. These early findings led to, 
among other things, HSCs being the first adult stem cells used successfully to treat 
and cure patients (14). 
Despite extensive research and wide application in modern medicine, the biology of 
the HSC compartment is still not fully understood and requires intense investigation 
to unravel the features of the HSC compartment.  
 
Figure 1: Schematic representation of hematopoietic development. This scheme illustrates the 
complex hematopoietic system, starting with the HSC and its differentiation into various lineages. 
HSCs sit at the top of the hematopoietic tree as they differentiate into progenitors that become 
progressively restricted to multiple or single lineages. The results of this cell differentiation are mature 
cells with several functions (6). CMP - Common Myeloid Progenitor; CLP - Common Lymphoid 
Progenitor; MEP - Megakaryocyte and Erythroid Progenitor; GM - Granulocyte and Macrophage 
Progenitor; TNK - T-Cell and Natural Killer Cell Progenitor; BCP - B-Cell Progenitor; MkP - 
Megakaryocyte; EP - Erythrocyte Progenitor; MP - Monocyte Progenitor; GP - Granulocyte Progenitor; 
TCP - T-Cell progenitor; NKP - Natural Killer Cell Progenitor; Partially adapted from reference (15). 
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3.1.1.1. Heterogeneity of the hematopoietic stem cell compartment 
Data from recent studies showed that the HSC compartment is not a homogenous 
population. It consists of several subpopulations of HSCs, each with distinct, pre-
programmed proliferation and differentiation behaviors (16). The theory of multi-
subpopulations is in contrast to the established opinion that the hematopoietic stem 
cell compartment is a homogenous population. However, it provides a better 
explanation for the complex behavior of the hematopoietic system. The widely 
accepted view was that 1 HSC gave rise to 1 myeloid and 1 lymphoid progenitor. 
However, this simplified theory could not explain the different ratios of myeloid to 
lymphoid cells in the blood. Additionally, this could not provide an explanation for the 
changes in blood cell composition during aging (17). These observations were first 
questioned by Jordan and Lemischka (18) using analysis of retrovirally marked 
HSCs, who suggested that there might be lineage-biased HSCs (16). The laboratory 
of Christa Müller-Sieburg was the first to discover that the normal HSC compartment 
consists of 3 different types of HSCs, which differ in their ability to differentiate into 
the different blood cell types (19, 20). Other research groups have made similar 
discoveries in recent years, resulting in a revolution in how the hematopoietic system 
is viewed today (21-24). The subsets can be classified by their differentiation 
potential, each with an epigenetic fixed differentiation and self-renewal capacity. 
Each subset consists of true HSCs, which give rise to all types of mature blood cell. 
However, the various types of HSCs induce different ratios of lymphoid and myeloid 
cells. These 3 subsets are named My-bi, Ly-bi, and Bala HSCs. Bala HSCs generate 
about 80% lymphocytes and 20% myeloid cells. Furthermore, My-bi HSCs produce 
few lymphocytes but normal numbers of myeloid cells, and thus have a low lymphoid 
to myeloid ratio. Ly-bi HSCs differentiate partially to myeloid cells, but produce 
normal numbers of lymphoid cells, resulting in a high ratio of lymphoid to myeloid 
cells (Fig. 2). In addition, these different subsets can be discriminated by their altered 
finite lifespans. In experiments using in vivo mice models and computer algorithms, it 
was shown that every HSC possesses an intrinsically limited life span (25). Notably, 
HSC clones differ markedly; some only live a few months, others survive several 
years. It was further demonstrated that My-bi HSCs have a higher self-renewal 
capacity than Ly-bi HSCs, resulting in the accumulation of My-bi HSCs in the aged, 
while Ly-bi HSCs dominate in young animals (17). Moreover, these subsets express 
different cell surface markers, which make it possible to enrich for the different HSC 
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compartments. One of these markers is CD150, which is expressed at higher levels 
on My-bi HSCs than on Ly-bi HSCs (21, 23, 24). Unpublished data, provided 
courtesy of Dr. Christa Müller-Sieburg and Dr. Hans Sieburg, show that with the aid 
of the marker CD150 it is possible to use fluorescence-activated cell sorting (FACS) 
for My-bi HSCs and Ly-bi HSCs. Sorting results in stem cell mixtures, but it can be 
assumed that the subset that is overrepresented after sorting is the one that is 
affected by the experiments performed in this thesis (Fig. 3). 
 
 
Figure 2: Hematopoietic stem cell heterogeneity. This diagram illustrates the novel view of the 
HSC compartment. The traditional model suggested only 1 type of HSC. However, more recent 
studies indicate that the HSC compartment consists of 3 distinct subsets with a certain epigenetically 
fixed differentiation (blue and red arrows) and self-renewal capacity (yellow arrow). The various types 
of HSCs give rise to different ratios of lymphoid and myeloid cells. Bala HSCs generate about 80% 
lymphocytes and 20% myeloid cells. My-bi HSCs generate few lymphocytes but normal amounts of 
myeloid cells and thus have a low lymphoid to myeloid ratio, while Ly-bi HSCs generate few myeloid 
cells but normal amounts of lymphoid cells, resulting in a high ratio of lymphoid to myeloid cells. 













	   10	  
Table 1: Summary of similarities and disparities between My-bi HSCs and Ly-bi HSCs 
  Ly-bi HSC My-bi HSC 
Stem cell classification multi-potent multi-potent 
Ratio lymphoid to 
myeloid cells 
normal lymphoid cells,  
few myeloid cells 
few lymphoid cells,  
normal myeloid cells 
Self-renewal capacity low self-renewal capacity high self-renewal capacity 
Pattern dominate in young animals accumulate in aged animals 
FACS markers 
c-Kit+; Sca-1+; lineage 
markers negative (Lin-); 
CD34-; CD150- (CD150neg) 
c-Kit+; Sca-1+; lineage 
markers negative (Lin-); 





Figure 3: Clonal analysis showed that CD150neg and CD150pos preparations contain long-term 
repopulating HSCs, which differ significantly by HSC lineage potential distribution. Bar charts 
show the distribution of lineage potential CD150neg or CD150pos sorted HSCs. This data and graph 
were provided courtesy of Dr. Christa Müller-Sieburg and Dr. Hans Sieburg and contain unpublished 
data. 
 
3.2 Leukemia  
Normal hematopoiesis malfunction may result in proliferation of certain blood 
components and a loss of normal functions of the blood. Transformation of the blood 
system was first described by John Bennett (1845) (26). He examined a patient post-
mortem, who had died rapidly after displaying signs of a “splenic tumor”. Microscopic 
examination of the blood revealed changes that were independent of inflammation 
and suggested a transformation affecting the whole blood. Bennett´s paper was the 
first published clinical case of a patient with leukemia. In line with Bennett´s 
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observations, Rudolf Virchow described a patient who died of a similar disease (27). 
Virchow introduced the name “leukhemia” (white blood) for an uncontrolled cell 
proliferation of white blood cells (28, 29). Interestingly, neither researcher could 
explain the cause or mechanism of this new disease. In the year 1869, Ernst 
Neumann drew a link between blood and bone marrow (30) and finally suggested 
that leukemia was a disease of the bone marrow (31). 
Today the diagnosis of leukemia is accompanied with a severe negative impact on 
the quality of peoples’ lives. About 13,000 people are diagnosed annually with some 
form of leukemia, resulting in leukemia being the 11th most common newly 
diagnosed tumor in Germany. Despite intensive research into treatment, 7,300 
people died from the consequences of leukemia in Germany in 2008 (32). Leukemia 
is a heterogeneous group of diseases. Each form of leukemia is described by a 
variety of symptoms, age of occurrence, therapies, and outcomes. In humans, 
leukemic cells can be classified by their morphological and immunological 
characteristics (i.e. acute and chronic forms). The acute forms are characterized by 
uncontrolled proliferation of immature cells referred to as blasts, whereas chronic 
forms display proliferation of mature but pathologically modified cells. Moreover, 
leukemic cells can be distinguished based on which types of blood cell they are 
derived from. Hence, it is possible to discriminate between a myeloid and a lymphoid 
form. If these 2 classifications are combined, they result in 4 different forms of 
leukemia, and this is the most common classification today (33). In particular, each 
form is determined by different age patterns as depicted in Figure 4. 
Despite the devastating numbers of patients and the great efforts that have been 
made in research, the causes of leukemia are still widely unknown, though some risk 
factors have been identified, such as exposure to ionizing radiation and aromatic 
hydrocarbons, particularly benzene. Furthermore, genetic factors have been 
implicated in the mediation of leukemia. Chromosome aberrations (trisomy 21) and 
chromosome translocation (Philadelphia translocation: t(9;22)(q34;q11)) have been 
suggested to increase the risk of leukemia. Nevertheless, most patients do not have 
any known risk factors (33, 34). 
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Figure 4: Age patterns of different forms of leukemia. The graphs show the age at diagnosis for 
leukemia in the United States between 2008 and 2012 for both genders. About 62,000 people are 
newly diagnosed with some form of leukemia every year in the United States. Occurrence of acute 
lymphoid leukemia peaks during childhood, whereas acute myeloid leukemia is more prevalent in 
older adults. Data from (35). 
	  
3.2.1. Acute myeloid leukemia (AML) 
The initial symptoms of AML are considered as unspecific. They are caused by an 
infiltration of blast cells in the bone marrow and a suppression of healthy bone 
marrow cells, which cause a failure of normal hematopoiesis. The results are fatigue 
and exhaustion caused by a lack of red blood cells. Furthermore, the lack of platelets 
may lead eventually to petechiae and mucous membrane bleeding. In addition, 
malfunction of the immune system can enable serious infections like pneumonia. It is 
possible to detect alterations caused by AML in blood tests, and in most cases the 
blood count shows a leukocytosis. Other variations are an increase in blast cells, 
anemia, and thrombocytopenia as well as enhanced levels of lactate dehydrogenase, 
blood sedimentation rate, and uric acid levels. Furthermore, to diagnose AML, 
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distinct parameters such as clinical symptoms, blood count, and a bone marrow 
biopsy are required. Crucial parameters for diagnosis are the specific numbers of 
blast cells in the bone marrow and their allotment to the myeloid lineage. Nowadays, 
2 classifications are commonly used. A precise classification is necessary to better 
predict the patients´ prognosis and to choose the appropriate therapy. The FAB-
classification (French-American-British) requires at least 30% of blast cells in the 
bone marrow. It is based on morphological and cytochemical characteristics of the 
cells, resulting in 8 subclasses (M0-M7). Depending on the subclass, the patients 
receive different prognoses and treatments (36-38). In addition, the World Health 
Organization (WHO) classification uses a clinical approach for its classification and 
divides the subtypes according to cytogenetic features. This approach was 
developed considering the FAB system and also considers underlying chromosomal 
abnormalities. It requires at least 20% of blasts cells in the bone marrow (39, 40). 
The current therapy for leukemia has 2 mainstays: chemotherapeutic agents and 
stem cell therapy. Chemotherapeutic agents are designed to specifically target 
rapidly growing cells; however, their action does not distinguish between cancer cells 
and healthy cells. Hence, treatment results in severe side effects including hair loss, 
nausea, and susceptibility to infection. Besides this, long-term effects lead to damage 
to nerves and the cardiovascular system. Thus, intense research is required for a 
better understanding of molecular changes and to find target cells of leukemic 
transformation, which might provide a more suitable therapy (36, 37). Stem cell 
transplantation is often the treatment of last resort for patients. There are 2 different 
methods used in stem cell transplantation - autologous and allogeneic 
transplantation.  In an autologous transplantation, the patient’s  own stem cells are 
returned after they have undergone high-dose chemotherapy. This method is mostly 
used to treat solid tumors. In an allogeneic transplantation, the patient receives stem 
cells from a healthy donor who has been matched for the HLA type. This type of 
transplantation is limited by the availability of a volunteering donor. It can take up to a 
month to find a suitable donor, and this delay can be critical for patients, especially 
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3.2.2 Leukemic stem cell 
In the last few years, the theory has been proposed that a small number of normal 
cells are transformed, which drives tumorigenesis and metastasis, resulting in the 
formation of cancer cells. Nevertheless, the initial transformed cell remains unknown 
in most cancer types. Cancer cells are characterized by an unlimited self-renewal 
potential, resulting in extensive proliferation (42). 
The hematopoietic system is one of the best-studied organ systems in terms of 
cancer cell theory. However, to date it is not known which cells are the target cells of 
leukemic transformation. This question is of major importance for clinical questions 
and patient outcome. 
It is assumed that leukemia arises from a transformation which takes place in a few 
or even single cells, which then leads to uncontrolled self-renewal and differentiation. 
It has been proposed that these transforming events take place in HSCs. 
Alternatively, leukemia may also arise from more committed progenitors (15). There 
is evidence suggesting that leukemia rises from an HSC. HSCs already have the 
ability to self-renew, which is an important aspect of a leukemic stem cell, and it 
seems more likely that this mechanism is turned into uncontrolled self-renewal than 
that self-renewal capacity is created in a cell which is already more differentiated. 
Another explanation why stem cells might be the target is that they are long-lived 
cells, and it also seems more likely that during their longer lifetime mutations could 
occur which transform these cells. On the other hand, there is some evidence that 
the leukemic transformation may take place in a progenitor cell. In mouse models 
using fusion genes like BCR-ABL and PML/RARα, it has been shown that myeloid 
leukemia also arises from more restricted progenitor cells (15). Another argument for 
the restricted progenitor is that HSCs are capable of differentiating into all lineages of 
the blood. However, in most cases leukemia only produces pathological cells from a 
single lineage. In this case a leukemic transformed progenitor, which is already 
committed to one lineage, could be a good explanation. 
	  
3.3. HoxA9 
HoxA9 is part of the homeobox gene family, which was first described in Drosophila.  
In mammals 39 different homeobox genes are known, which are arranged into 4 
clusters and labeled A, B, C, and D (43, 44). 
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These genes play an important role during embryonic development, where they are 
essential for specifying cell identity and positioning. Mutations in these genes can 
result in morphologic abnormalities involving many body structures (45). 
During development HoxA9 plays an important role in many parts of the body, for 
example in skeletal tissue or urogenital tract development. HoxA9 is also known to 
play a role in cancer, for example, it is downregulated in breast cancer (46).  
HoxA9 is best known for its crucial role during hematopoiesis. It is the most highly 
expressed gene of the homeobox family in HSCs and plays an essential role during 
normal hematopoiesis. However, abnormal expression can lead to abnormal stem 
cell behavior and cell expansion, and eventually to leukemia. HoxA9 is highly 
expressed in early hematopoietic progenitors whereas it is downregulated during 
differentiation (47-49). On the other hand, loss of HoxA9 expression during early 
stages of hematopoiesis results in a hematopoietic phenotype with reduced numbers 
of peripheral blood granulocytes and lymphocytes (50). In patients with AML the 
expression of HoxA9 is associated with a poor prognosis, and about 50% of patients 
with AML express HoxA9. The overexpression of HoxA9 leads to AML in mice, which 
makes this gene a valuable tool for leukemia studies (51). Nevertheless, it remains 
unknown by which molecular mechanisms HoxA9 promotes leukemogenesis (48, 
52). 
 
3.4. Aim and outline of the thesis 
3.4.1. Motivation and goal 
Despite extensive research and great progress in treatment, the prognosis for 
patients with acute leukemia is still poor. New insights, specifically the heterogeneity 
of the HSC compartment, offer many novel opportunities to address questions that 
could not be investigated before. Nevertheless, it still remains enigmatic which cells 
are the preferred target cells for leukemic transformation. Identifying the preferred 
target cell population would be an important step towards the development of more 
efficient therapeutic approaches. 
This thesis was designed to analyze whether My-bi HSCs are a target of 
transformation in myeloid leukemia. If the hypothesis is true, this could explain why a 
transformed HSC has progeny skewed toward the myeloid lineage. Furthermore, My-
	   16	  
bi HSCs accumulate in the aged animal. This fits well with the clinical observation 
that acute myeloid leukemia occurs more frequently in the elderly. The aim of this 
thesis is to show whether My-bi HSCs and Ly-bi HSCs behave differently when 
transduced with a retroviral vetctor overexpressing a gene that induces AML. Another 
question we want to answer is whether My-bi HSCs are the target cells for leukemic 
transformation induced by HoxA9. 
	  
3.4.2. Outline 
1. How do My-bi and Ly-bi cells transduced with HoxA9 repopulate in the 
blood? 
To answer this question, whole bone marrow cells were sorted for LSK+ CD34+ to 
collect highly purified HSCs. These cells were further sorted to select a CD150+ or 
CD150- population. The acronym CD150pos/HSCs is used to refer to the cell 
population that is enriched for My-bi HSCs. On the other hand, the acronym 
CD150neg/HSCs is used for the cell population that is highly enriched for Ly-bi HSCs. 
The sorted cells were then transduced with a retroviral vector overexpressing HoxA9. 
For these transduced cells the acronym CD150neg/HoxA9 HSCs or CD150pos/HoxA9 
HSCs is used. Transduced cells were then injected into lethally irradiated mice. 
These mice are called primary host mice. The repopulation levels of donor cells and 
transduced donor cells that express the HoxA9 gene were monitored in primary host 
mice using the cell surface marker CD45.1 and GFP (green fluorescent protein). The 
blood levels were monitored for a period of 5 months. 
 
2.  Is HoxA9 capable of inducing leukemia in My-bi and Ly-bi HSCs?  
If a primary or secondary host mouse showed signs of leukemia, the mouse was 
sacrificed and the spleen weight was used as an indicator for leukemia. Signs of 
leukemia were lethargy, lack of motion, and refusal to eat. 
 
3. What cell marker changes can be seen in the blood? 
Control samples of blood were drawn after 1, 3, and 5 months. The blood was then 
analyzed for the composition of B-cells, T-cells, and myeloid cells. To visualize the 
HoxA9 activity, the overexpressing gene was linked to GFP. 
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4. Which roles do the bone marrow and spleen play in leukemic behavior?  
If a primary host mouse showed signs of leukemia, the mouse was sacrificed and the 
bone marrow and spleen were analyzed further. An age-matched mouse from the 
other group (either CD150pos/HoxA9 or CD150neg/HoxA9) was euthanized at the 
same time and was used to compare the progress of leukemia. 
 
5. Does the leukemic behavior stay consistent after serial transplantation of 
bone marrow cells into new host mice?  
To observe if the type of leukemia stayed consistent and to further observe leukemic 
behavior, several serial transplantation experiments were performed. Therefore, 
whole bone marrow from the primary host mice was injected into lethally irradiated 
mice. These mice are called secondary host mice. Blood from these mice was drawn 
at the same intervals, and the same analyses were used as for the primary mice. 
 
6. Does the leukemic behavior differ if spleen cells are serially transplanted 
compared to bone marrow cells?  
To provide deeper insights in the composition of bone marrow and spleen and to 
address the question of whether the spleen could be a place of extra-medullary 
hematopoiesis, serial transplantations with spleen and bone marrow from leukemic 
mice were performed. Therefore, bone marrow cells or spleen cells from secondary 
host mice of both groups were injected into lethally radiated mice. These mice are 
called tertiary host mice. These mice were observed for the length of their survival 
time. 
 
7. Does the number of transplanted cells impact the leukemic behavior? 
To demonstrate that the number of transplanted cells has no impact of the onset, 
behavior, and type of leukemia, different numbers of whole bone marrow cells were 
transplanted from the primary into the secondary host mice for both CD150pos/HoxA9 
and CD150neg/HoxA9 groups. 
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4. Material and Methods 
4.1. Buffers and solutions  
Table 2: The composition of buffers and solutions 
	  
Medium/Solution Composition 
Bone Marrow Culture 
Medium (BMCM) 
500 mL RPMI-1640, 10 mL GluPest, 25 mL Fetal Calf Serum, 
0.5 mL Beta Mercapato-Ethanol 
GluPest 200 mM L-Glutamine, 5000 Units/mL Penicillin/Streptomycin 
Staining Medium 500 mL Newborn Calf Serum, 33.3 mL of 10% Sodium Azide, 2170 mL dH20, 250 mL of 10X dPBS 
Propidium Iodide (PI) 
Medium staining medium with 10 µg/mL PI 
Sterile PI Medium staining medium with 10 µg/mL PI, sterile filtered 
Basal Medium 400 mL  Iscove's Modified Dulbecco's Medium (IMDM), 75 mL Fetal Calf Serum, 25 mL GluPest 
FACS Medium 400 mL IMDM, 100 mL Fetal Calf Serum 
Cytokine Medium 
5 mL Basal Medium, 25 µL mSCF(100ng/mL), 25 µL hIL6(10 
ng/mL), 37 µL Thrombopoietin TPO(75 ng/mL), 5 µL bFGF (10 
ng/mL), 5 µL Flt3-1(10 ng/mL), 5 µL FGF (10 ng/mL) 
293T Medium 
25 mL Fetal Calf Serum, 217.5 mL Isocoves IMDM, 2.5 mL 
MEM Non-Essential Amino Acids Solution (100X), 5 mL 
GluPest 
S17 Medium 250 mL Alpha-MEM, 50 mL Fetal Calf Serum 
Dexter Medium 
50 mL IMDM, 75 mL horse serum (HS), 75 mL FBS, 5 mL 200 
mM L-glutamine, 2.5 mL 10,000 U/mL penicillin/10,000 µg/mL 
streptomycin, 500 µL 0.1 M 2-mercaptoethanol, 500 µL 1 mM 
hydrocortisone 
10 mM PBS/EDTA 5.13 mL 0.5M EDTA, bring volume to 200 mL with 1xPBS, add HCI until pH is 7.0 
Lysogeny Broth (LB) 
10 g tryptone, 5 g yeast extract, 10 g NaCl in 950 mL DI H2O,  
adjust pH  to 7.0 using 1N NaOH and bring volume up to 1 
liter, autoclave on liquid cycle for 20 min at 15 psi, add 
ampicillin 50 µg/mL 
LB agar-plates 
Prepare LB medium, but add 15 g/L agar before autoclaving, 
after autoclaving add ampicillin 50 µg/mL and pour into Petri 
dishes 
Gey Solution Stock A 
35 g NH4Cl, 1.85 g KCl, 1.5 g Na2HPO4*12H2O, 0.12 g 
KH2PO4, 5 g Glucose, bring volume to 10 mL with DI H2O, 
sterile filtered 
Gey Solution Stock B 0.42 g MgCl12*6H2O, 0.14 g MgSO4*7H2O, 0.34 g CaCl2, bring volume to 100 mL with DI H2O, sterile filtered 
Gey Solution Stock C 2.25 g NaHCO3, bring volume to 100 mL with DI H2O, sterile filtered 
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 Table 2: Continued 
Medium/ Solution Content 
2% Dextran 10 g of Dextran T500, bring volume to 500 mL with PBS 
2% Bovine Serum 
Albumin 





Table 3: Antibodies used for these experiments 





rat primary Ab BioLegend, San Diego CA, USA 
GR-1 Antibody (RB6-8C5) rat primary Ab Life Technologies, Carlsbad CA, USA 
Anti-Mouse CD11b 
Purified (Mac-1) rat primary Ab 
Biosciences, Franklin 
Lakes NJ, USA 
Anti-Mouse Thy-1 
Antibody (31-11) rat primary Ab 
Santa Cruz Biotechnology, 
Santa Cruz CA, USA 
Mouse Anti-Mouse 
CD45.1-APC (Ly-5.1) mouse primary Ab 
SouthernBiotech, 
Birmingham, AL, USA 
FITC anti-mouse Ly-6A/E 
(Sca-1) Antibody rat primary Ab 
BioLegend, San Diego CA, 
USA 
PE anti-mouse CD34 
Antibody 
Armenian 
hamster primary Ab 
BioLegend, San Diego CA, 
USA 
APC anti-mouse CD117 
(c-Kit) Antibody rat primary Ab 





hamster primary Ab 
BioLegend, San Diego CA, 
USA 
PE/Cy7 anti-mouse 
CD150 (SLAM) Antibody rat primary Ab 
BioLegend, San Diego CA, 
USA 
PE Goat anti-rat IgG 
(minimal x-reactivity) 
Antibody(G@RPE) 
goat secondary Ab 
BioLegend, San Diego CA, 
USA 
APC/Cy7 Streptavidin Streptomyces avidinii 
secondary 
Ab 
BioLegend, San Diego CA, 
USA 
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4.3. Mice  
C57BL/6 (B6) mice were purchased from Jackson Laboratories (Bar Harbor, ME, 
USA). All other mice were bred at the Sanford-Burnham facility. These included B6 
mice congenic for the CD45.1 allele (B6-CD45.1) and F1 mice. F1 mice are 
generated by mating a B6-CD45.1 mouse with a B6-CD45.2 mouse. The blood cells 
express both a CD45.1 and a CD45.2 gene. David Harrison (Jackson Laboratories, 
Bar Harbor, ME, USA) generously provided the breeder pairs of B6-W41W41 mice; 
these mice have a mild mutation in the c-Kit gene and served as sublethally 
irradiated hosts for transplantation experiments (17). The work reported in this 
dissertation was supported by the United States National Health Grants DDK48015 
and AG 023197 to Prof. Dr. Christa E. Muller-Sieburg. Experiments, if any, were 
performed in Prof. Dr. Muller-Sieburg's laboratory at the Sanford-Burnham Institute in 
La Jolla, California. All experiments were approved by the Institutional Animal Care 
and Use Committee at the Sanford-Burnham Institute in La Jolla, California. 
	  
4.4. Plasmid MigR1- HoxA9 
The MigR1-HoxA9 construct contains the GFP reporter under control of the HoxA9 
promoter and an ampicillin resistance cassette (Fig. 5). This plasmid was transfected 
into a retrovirus (see 4.7.) and the resulting retroviral vector was later used to 
transduce the target cells (see 4.8.). 
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Figure 5:  MigR1-HoxA9 plasmid. The plasmid consists of a total of 7,343 base pairs (bp). It contains 
the GFP reporter under control of the HoxA9 promoter. This means that when HoxA9 is expressed 
GFP will also be expressed. The ampicillin resistance cassette helps to select the bacterial colonies 
that have incorporated the plasmid during transformation (see 4.5 Transformation). The possible 
restriction enzyme cutting locations are marked in blue. Thanks are due to Dr. Jeffrey Bernitz for 
providing the plasmid construct. 
	  
4.5. Transformation  
We mixed 1 µL of MigR1-HoxA9 DNA (see 4.4.) with competent Escherichia coli 
(E.coli) cells and incubated for 30 minutes on ice. After incubation, the tube was 
removed from the ice and put in a 42°C heated block for 90 seconds. Then, the tube 
was returned to ice for 5 minutes, and 500 µL of lysogeny broth (LB) was added to 
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the cells. They were then transferred to a sterile falcon tube and incubated for 1 hour 
with shaking at 37°C. Afterwards, the cells were plated on LB plates supplemented 
with 50 µg/mL ampicillin and incubated overnight at 37°C. Only bacteria that had 
incorporated the plasmid had the resistance gene for ampicillin and were able to 
grow on the plates. The following day single colonies were picked up with sterile tips 
and grown in 5 mL LB medium supplemented with 50 µg/mL ampicillin for 8 hours 
with shaking at 20°C. 
	  
4.6. Isolation of plasmid DNA 
Bacteria from at least 5 cultures were pelleted via centrifugation for 7 minutes at 312 
RCF(g) in a tabletop centrifuge. Isolation of plasmid DNA was then performed with a 
QIAGEN Plasmid Midi Kit (Qiagen N.V., Venlo, Netherlands) according to the 
manufacturer’s instructions. Finally, the plasmid DNA pellet was air-dried for 5-10 
minutes and redissolved in 100 µL TE buffer, pH 8.0. The concentration of DNA was 
determined by measuring the absorbance at 260 nm (A260) in a spectrophotometer. 
 
4.7. Producing the retroviral vector; transfection 
On the first day, 2x107 293T cells were plated in a 15 cm dish with 30 mL of medium. 
The next day, 24 µg of Plasmid Migr1-HoxA9 DNA (see 4.4.) was mixed with 8 µg 
ECOpack DNA (Clonetech, Mountain View, CA, USA). Additionally, 144 µL of 
FuGENE (Roche Applied Science, Basel, Switzerland) was added dropwise to 2 mL 
of Opti-MEM medium (Life Technologies, Carlsbad, CA, USA) and then rested for 5 
minutes at room temperature. Then, the DNA mix was added dropwise to the solution 
with FuGENE, and everything was gently shaken and rested for 20 minutes at room 
temperature. In the meantime, the medium from the 293T cells was aspirated and 
replaced with 10 mL of fresh medium. The DNA and FuGENE mix was added 
dropwise to the 293T cells, and everything was incubated at 37°C overnight. The 
next day 10 mL of medium was added to the 293T cells, and the plate was incubated 
for another 2 days at 37°C. After the incubation time, the media containing the 
retroviral vector was collected and centrifuged for 10 minutes at 312 RCF(g). At the 
next step, the supernatant was filtered through a 40 µm filter (FalconTM Cell Strainers, 
Fischer Scientific, Waltham, MA, USA), aliquoted, and immediately stored at -70°C. 
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4.8. Retroviral transduction of HSCs 
After sorting, the cells were centrifuged and then seeded into a Falcon 24-well Tissue 
Culture Plate (Corning Life Sciences, Corning, NY, USA) in cytokine medium for 2 
days. The following day, 4 wells of another 24-well plate were coated with 
RetroNectin (RN) (Clontech Mountain View, CA, USA) solution and then rested 
overnight at 4°C. The next day, the virus-loaded plates were prepared. For this, the 
RN solution was removed, 2% BSA was added, and the plates rested for 30 minutes 
at room temperature. Afterwards, the wells were washed with Dulbecco's Phosphate-
Buffered Saline (dPBS) (lonza Group, Basel, Switzerland). Then, 0.5 mL of the virus 
supernatant containing the retroviral vectors (see 4.7.) overexpressing HoxA9 was 
added to 2 of the 4 wells. The other 2 were kept as control wells, and everything was 
incubated for 5 hours at 32°C. After incubation, the wells were washed once again 
with dPBS, and the transduction was performed. The sorted cells that were in pre-
stimulation conditions were transferred to the Hoxa9 retrovirus-loaded wells. The 
following day all cells were collected and washed with Iscove’s Medium (IMDM) 
(Lonza Group, Basel, Switzerland). The cells were centrifuged and resuspended in 
IMDM. They were then ready for injection into sublethally irradiated B6-W41W41 
mice. 
	  
4.9. Harvesting of bone marrow 
The mice were anesthetized using isoflurane (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and an anesthesia vaporizer (Parkland Scientific, Inc., Coral Springs, 
FL, USA). Subsequently, mice were sacrificed by cervical dislocation. Next, 97% 
ethanol was applied to clean the fur. For the extraction of bone marrow, skin and 
muscles were separated from the tibia and femur using forceps and scissors. In the 
next step, these bones were separated from the rest of the body and stored on ice in 
bone marrow culture medium (BMCM). Separation of bone marrow was performed 
using a 10 mL syringe containing BMCM, which was injected into the bone in order to 
flush out the bone marrow. The obtained bone marrow was centrifuged for 7 minutes 
at 312 RCF(g) in a tabletop centrifuge (Hettich Rotina420R, Hettich Instruments LP, 
Beverly, MA, USA). Finally, the supernatant was discarded and 1 mL of BMCM was 
added to the pellet and the cells resuspended. In order to determine the number of 
extracted cells, a cell count was performed (see 4.14.). 
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4.10. Sorting of HSCs 
In order to sort the bone marrow cells into fractions of CD150pos and CD150neg HSCs, 
cells were labeled with fluorescent antibodies and sorted using a FACSaria (BD 
Biosciences, Franklin Lakes, NJ, USA). Cells isolated from bone marrow (B6-CD45.1 
mice) were counted (see 4.14.); 1.0x107 cells were used for sorting and 1.0x106 cells 
were used for each of the compensation tubes. The cells for sorting were put into a 
Falcon 15 mL Conical Centrifuge Tube, and 106 cells for compensation were put into 
Falcon FACS-tubes (both BD Biosciences, Franklin Lakes, NJ, USA). All tubes were 
centrifuged for 7 minutes at 312 RCF(g) in a tabletop centrifuge. The supernatant 
was aspirated and discarded, and the pellet was dispersed. Then primary antibodies 
were added. The combinations of antibodies used are described in Table 4, and 6 µL 
of each antibody was added per 106 cells. All tubes were incubated at 4°C for 15 
minutes. After incubation, the cells for sorting were washed with 10 mL of staining 
medium, and the cells for compensation with 1 mL of staining medium. All tubes were 
centrifuged for 7 minutes at 312 RCF(g) in the tabletop centrifuge. The supernatant 
was aspirated and discarded, and the pellet was dispersed again. Then, the 
secondary antibody was added to the comp APC-Cy7 tube and to the cells for 
sorting. The tubes were incubated at 4°C for 15 minutes. After incubation the cells for 
sorting were washed with 10 mL of staining medium, and the cells for compensation 
with 1 mL of staining medium. All tubes were centrifuged as before, and the 
supernatant was aspirated and discarded. The pellets of the compensation tubes 
were resuspended with 200 µL of staining media. For the single PI compensation, 
200 µL of PI medium was used for resuspension. Then 2 mL of staining medium was 
added to the cells for sorting and the cells were filtered through a nylon mesh 
(FalconTM Cell Strainers, Fischer Scientific, Waltham, MA, USA). The mesh was 
washed with 5 mL of PI staining media to collect all remaining cells. The cells for 
sorting were centrifuged again, and the supernatant was aspirated and discarded. 
The pellet was resuspended in 2 mL of sterile PI staining medium. The cells were 
now ready for sorting. Two tubes with 5 mL sorting media were prepared for 
collecting the sorted cells. The cells were sorted with a FACSaria and the gates were 
set for white blood cells, living cells, lin-, Sca+, c-Kit+, CD34- and CD150+/- (Fig. 6), 
with the help of the FACS-facility supervisor. 	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unstained - - - - - - - 
comp FITC + - - - - - - 
comp PE - + - - - - - 
comp PI - - - - - - + 
comp APC - - + - - - - 
comp APC-
Cy7 - - - + + - - 
comp PE-cy7 - - - - - + - 
sample to sort + + + + + + + 
 
 
Figure 6: Protocol for sorting HSCs. 4,025,000 whole bone marrow cells were sorted and the gates 
were set for white blood cells (P1, doublet gate 1, doublet gate 2), Live cells, Lin-, c-Kit+ and Sca1+, 
CD34- and CD150+ or CD150-. The beginning population of 4,025,000 bone marrow cells was sorted 
into 916 CD150pos HSCs and 1158 CD150neg HSCs.  
	  
4.11 Performing a blood test 
Repopulation levels were monitored by staining white blood cells with monoclonal 
antibodies (mAb) specific for the CD45.1 allele. The HoxA9 activity was measured 
with GFP at the same time. The white blood cells were stained with mAb specific for 
Thy-1 (31-11/T-lymphocytes), B220 (6B2/B-lymphocytes), and Gr-1 
(8C5/granulocytes) and Mac-1 (macrophages). The final samples were run on a 
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FACSCalibur (BD Biosciences Franklin Lakes, NJ, USA) and analyzed using FlowJo  
software (FLOWJO, LLC Ashland, OR, USA) (Fig. 7).  
A preparation of 500 µL of 10mM PBS/EDTA was added to Falcon FACS-tubes (BD 
Biosciences Franklin Lakes, NJ, USA) to prevent coagulation of the blood and the 
tubes were kept on ice. The mice were warmed for about 5 minutes under a heating 
lamp. A single mouse was put in a mouse restrainer, and the tail was slightly cut with 
a razorblade; then about 4-6 drops of blood were collected in the FACS-tubes. The 
tubes were gently shaken to mix the blood completely with the PBS/EDTA and 
prevent coagulation. After bleeding all the mice, 1 mL of 2% Dextran (T-500 Dextran 
Pharmacosmos Holbaek, Denmark) was added to each tube and the tubes were 
incubated at 37°C for about 40 minutes. After the incubation time, the red blood cells 
had settled on the bottom of the tubes. The clear supernatant, which contained the 
white blood cells, was carefully transferred with a disposable plastic transfer pipette 
to new FACS-tubes. The supernatant was washed by adding 1 mL of staining media 
to each tube and was centrifuged for 7 minutes at 312 RCF(g) in a tabletop 
centrifuge. After spinning, the supernatant was decanted into the sink and the pellet, 
which contained a few remaining red blood cells and enriched white blood cells, was 
dispersed by shaking the tube holder vigorously back and forth 3-4 times. The 
remaining red blood cells were lysed with Gey solution by adding 1 mL of Gey 
solution and incubating the mixture for 90 seconds. The Gey solution was neutralized 
with 1 mL of staining media. Afterwards, the contents were centrifuged for 7 minutes 
at 312 RCF(g) in a tabletop centrifuge. The clear supernatant was decanted into the 
sink and the pellet was dispersed by shaking the tube holder vigorously back and 
forth 3-4 times. Then,100 µL of staining media was added, the solution was split into 
3 new FACS-tubes, and 30 µL of 1x solution of the primary antibody Ly-APC was 
added to every tube. Also, 30 µL of 31-11, 6B2, and 8C5/Mac-1 antibodies were 
added to the corresponding tubes as shown in Table 5. The cells were incubated for 
15 minutes at 4°C, protected from light, and after incubation 1 mL staining medium 
was added to remove unbound antibodies. After another centrifugation, the 
supernatant was decanted. Subsequently, the secondary antibody G@RPE was 
added to the tubes and incubated for 15 minutes at 4°C while protected from light. 
After a final washing step with 1mL staining media, 200 µL of PI medium was added 
to each tube except the non-PI single color control tubes (usually control tube 1). 
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Figure 7:  Gating of blood samples. The samples were analyzed with a FACSCalibur flow cytometer 
and  FlowJo software. First (1.), the cells were gated for SSC (indicator for cell size) against FSC 
(indicator for granularity). This allowed the identification of the lymphocytes. Then (2.), the 
lymphocytes were gated for PI, which helped to distinguish between live and dead cells. The next step 
(3.) was to gate the live lymphocytes for GFP+ and CD45.1 (Ly+). This only identified transplanted 
lymphocytes (CD45.1) that were transduced with the retroviral vector (GFP). The final step (4.) was to 
gate these cells for the linage marker, which could be 31-11, 6B2, or 8C5/Mac-1 to distinguish 
between T-cells, B-cells, and myeloid cells. 
 
Table 5: Antibody combinations used for blood sample analysis 
Tubes Antibodies 
Control tube 1 - -  G@RPE 
Control tube 2 - 31-11  G@RPE 
Control tube 3 Ly-APC -  G@RPE 
Control tube 4 Ly-APC 31-11  G@RPE 
Control tube 5 Ly-APC 6B2  G@RPE 
Control tube 6 Ly-APC 8C5/Mac-1  G@RPE 
    
Test tube 1 Ly-APC 31-11 G@RPE 
Test tube 2 Ly-APC 6B2 G@RPE 
Test tube 3 Ly-APC 8C5/Mac-1 G@RPE 
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4.12. Harvest of spleen 
The mice were narcotized with isoflurane (Santa Cruz Biotechnology, Santa Cruz 
CA, USA) and the help of an anesthesia vaporizer (Parkland Scientific Inc., Coral 
Springs, FL, USA). After narcotizing, the mice were sacrificed by cervical dislocation 
and the fur was cleaned with 97% ethanol. The abdomen was carefully opened with 
scissors and the organs were observed. Photographs were taken, and then the 
spleen was carefully removed and freed from fat. After that, the weight and length of 
the spleen was measured. A BD Falcon Cell Strainer (40 µm, blue) was placed on a 
BD Falcon 50 mL conical tube (both BD Biosciences Franklin Lakes, NJ, USA). The 
spleen was cut into multiple pieces and squeezed through the filter. Then, 1 mL of 
BMCM was added to the top of the filter and the spleen was squeezed through again. 
Afterwards, another 1 mL of BMCM was added, and with the help of a pipette the last 
drops were pulled through the filter. The contents were resuspended with a 1 mL 
pipette tip, and the spleen cells were centrifuged for 7 minutes at 312 RCF(g) in the 
tabletop centrifuge. Then the supernatant was aspirated and 1 mL of BMCM was 
added. A cell count was taken (see 4.14). 
 
4.13. Staining of bone marrow and spleen cells 
For staining experiments, 1x106 cells were utilized, and 30 µL of 1x solution of the 
primary antibody Ly-APC was added to every tube. Also 30 µL of 31-11, 6B2, 8C5, 
and Mac-1 were added to the corresponding tubes (Table 6). Further washing and 
staining was performed as described in 4.11. 
 
Table 6: Antibody combinations used for bone marrow and spleen samples 
Tubes	   Tissue	   Antibodies	  
Tube 1 BM BM       
Tube 2 BM BM 6B2 GaR-PE Ly-APC 
Tube 3 BM BM 8C5 GaR-PE Ly-APC 
Tube 4 BM BM Mac-1 GaR-PE Ly-APC 
     
Tube 1 Spleen Spleen       
Tube 2 Spleen Spleen 31-11 GaR-PE Ly-APC 
Tube 3 Spleen Spleen 6B2 GaR-PE Ly-APC 
Tube 4 Spleen Spleen 8C5 GaR-PE Ly-APC 
Tube 5 Spleen Spleen Mac-1 GaR-PE Ly-APC 
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4.14. Counting cells 
For counting cells, a new dilution was made with 190 µL Turk’s solution and 10 µL of 
the corresponding cell suspension. Turk’s solution stains the nuclei of leukocytes and 
hemolyzes erythrocytes which makes it easy to visualize and count leukocytes. The 
cell count was made using a hemocytometer. 
	  
4.15. Producing and staining slides 
A solution of 106 bone marrow cells in 1 mL staining media was prepared, and 100 
µL of this cell solution was put in a CytoSep™ funnel and centrifuged in a Shandon 
Cytospin 4® (Thermo Scientific, Waltham, MA, USA) for 10 minutes at 412 RCF(g). 
The centrifuge chambers were prepared with microscope slides and filters so that the 
cells were centrifuged as a drop onto the microscope slides. After air-drying, 2 drops 
of Wright-Geimsa stain were added to the slides for 2 minutes. Afterward, 2 drops of 
distilled water (DI H2O) were added and the slides were incubated for another 2 
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5. Results 
The aim of this thesis was to study the leukemic behavior of transduced CD150pos 
HSCs and CD150neg HSCs in vivo. Therefore, these cells were transduced with a 
retroviriral vector overexpressing HoxA9 and injected into host mice. Blood samples 
were drawn and analyzed with fluorescent antibodies and FACS analysis. After 
symptoms of leukemia developed, mice were sacrificed and the spleen and bone 
marrow were analyzed. Both CD150pos and CD150neg are a heterogenic mixture of 
different HSCs (Fig. 3). This means that  CD150pos HSCs contain mostly My-bi 
HSCs, but also some Ly-bi HSCs and Bala HSCs, and vice versa for the CD150neg 
HSCs that mostly contain Ly-bi HSCs. However, it can be assumed that the 
overrepresented HSC subtype is the one, which gets transduced by the retroviral 
vector. This means that for the CD150pos HSCs, My-bi HSCs are the ones that 
become transduce, and vice versa for the CD150neg where the Ly-bi HSCs are 
transduced. Seventeen primary mice received CD150neg/HoxA9 HSCs and also 17 
received CD150pos/HoxA9 HSCs (see 5.1.). If the percentage of GFP+ cells was 
below 2% at time of sacrifice in any of the 3 tested tissues (blood, spleen or bone 
marrow) a reasonable analysis was not possible and these mice were excluded from 
further analysis. Details for further exclusion of mice and possible reasons for this are 
discussed under 6.6. Limitations. This resulted in 10 primary host mice that received 
CD150neg/HoxA9 HSCs and 6 primary host mice that received CD150neg/HoxA9 
HSCs that were used for detailed analysis (5.2. and onward). For the secondary 
hosts, 4 mice each were analyzed for the CD150neg/HoxA9 respectively 
CD150neg/HoxA9 group. 
 
5.1. How do My-bi and Ly-bi HSCs transduced with HoxA9 
repopulate in the blood? HoxA9 slowed down the growth of 
CD150pos HSCs 
The blood levels of transplanted cells were analyzed in the mice after 1, 3, and 5 
months. Repopulation levels were monitored by staining white blood cells with 
monoclonal antibodies specific for the CD45.1 allele. CD45.1(Ly5.1) is a marker that 
is expressed on all donor cells that were transplanted. A total of 17 mice were 
transplanted with cells from each group, one group received CD150pos/HoxA9 HSCs, 
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and the other CD150neg/HoxA9 HSCs. For 12 mice of each group, data points at 1, 3, 
and 5 months were available. For the remaining 5 mice, 1 or 2 data points were 
missing. This was for different reasons - for example because some mice were 
euthanized earlier than 5 months because they showed signs of leukemia. 
The mice transplanted with CD150pos/HoxA9 HSCs have a higher percentage of 
donor-type cells compared to the CD150neg/HoxA9 group. All mice that received 
CD150pos/HoxA9 HSCs showed an increase of donor cells over the 5-month 
experiment duration. In mice that received CD150neg/HoxA9 HSCs the mean 
percentage of donor-type cells stayed almost the same after 5 months.  
The next step was to analyze how many of the donor cells were expressing the 
HoxA9 gene. Therefore, the GFP levels of donor cells were measured in the blood. 
Mice that received CD150pos/HoxA9 HSCs showed a decline in the number of cells 
expressing the HoxA9 gene, in contrast to the CD150neg/HoxA9 mice that showed an 




Figure 8: Comparison of the kinetics of donor-type cells in primary host mice. Donor-type cells 
were measured at 1, 3, and 5 months (horizontal axis) after transplantation. The graphs show the 
mean and the standard deviation (SD) of donor-type cells (blue) or GFP+ donor-type cells (red). The 
mice that received CD150pos/HoxA9 HSCs (3 months n=12) had higher numbers of donor-type cells 
and showed an increase over 5 months compared to the mice that received CD150neg/HoxA9 HSCs (3 
months n=12). A 2-sided t-test between the 2 groups was significant (P<0.05) for all months. 
Interestingly, the donor-type cells expressing the HoxA9 gene (GFP+) behaved differently. The mice 
that received CD150pos/HoxA9 HSCs showed a decrease in  GFP+ donor cells from 8.9% at 1 month 
(n=17) to 4% at 5 months (n=12). However, the CD150neg/HoxA9 mice showed an increase of cells 
that express HoxA9, from 6.1% at 1 month (n=17) to 9% at 5 months (n=12).  
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5.2. Is HoxA9 capable of inducing leukemia in My-bi and Ly-bi 
HSCs? Mice injected with CD150neg/HoxA9 HSCs showed an 
enlarged spleen 
As AML causes splenomegaly, the spleen weight was used as an indicator for the 
progress of leukemia. Differences in spleen size were already seen macroscopically 
(Fig. 9). For the CD150neg/HoxA9 HSC population (mean=0.17 g; SD=0.07 g; n=10) 7 
out of 10 mice showed an enlarged spleen >0.15 g. This was in contrast to the 
CD150pos/HoxA9 HSCs group (mean=0.09 g; SD=0.02 g; n=6) where none of the 6 
analyzed mice showed an enlarged spleen at time of death. An unpaired t-test was 
significant with a P value of 0.006 for the spleen weights of both groups.  
No signs of leukemia were observed in primary host mice that received 
CD150pos/HoxA9 HSCs. To further examine the leukemic behavior, whole bone 
marrow cells from primary host mice were serially transplanted into secondary host 
mice.  Interestingly, 2 to 2.5 months post-transplantation, spleens of secondary host 
mice displayed enlarged morphology (Fig. 10). Moreover, in all secondary host mice 
treated with CD150neg/HoxA9, we observed spleens markedly increased in size. In 
contrast to the primary host, all 4 secondary host mice of the CD150pos/HoxA9 group 
(mean=0.25 g; SD=0.09 g; n=4) also showed an enlargement (spleen weight >0.15 
g). Nevertheless, the spleens of the CD150neg/HoxA9 mice (mean=0.36 g; SD=0.08 
g; n=4) were slightly bigger.  
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Figure 9: Comparison of spleen size of primary host mice. Primary host mice were injected with 
HSC subsets and sacrificed at 208 days post-transplantation. As a control mouse an age-matched 
untreated animal was used. The spleens were freshly harvested, and the surrounding fat tissue was 
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Figure 10: Spleen weights of primary and secondary host mice (mean and SD).  Spleen weight 
(vertical axis), at time of death, of primary and secondary host mice injected with CD150pos HoxA9 
transduced HSCs or CD150neg HoxA9 transduced HSCs. For CD150neg/Hoxa9 HSCs (mean=0.17g; 
SD=0.07g; n=10), 7 out of 10 primary mice showed an enlarged spleen >0.15g in contrast to 
CD150pos/Hoxa9 HSCs (mean=0.09g; SD=0.015; n=6), where none of the 6 analyzed primary mice 
showed an enlarged spleen at time of death. All secondary host mice showed an enlargement of the 
spleen (spleen weight >0.15g). Nevertheless, the spleens of the CD150neg/HoxA9 mice (n=4) were 
slightly bigger than the CD150pos/HoxA9 mice (n=4). The control mice (n=4) were age-matched 
animals that were not injected with any cells. 
 
5.3. Mice injected with CD150neg/HoxA9 HSCs showed higher HoxA9 
activity 
The HoxA9 activity is linked to GFP expression, which makes it possible to measure 
the activity of HoxA9. At time of euthanasia, the mouse cells were stained for 
CD45.1, and then the percentages of GFP+ cells for blood, spleen, and bone marrow 
were checked with a FACSCalibur cytometer (Fig. 11). The data showed that in both 
groups the activity of GFP in the blood was about 16%, and was significantly lower 
than in the bone marrow for both groups together P< 0.0001 in a paired t-test. 
Interestingly, the GFP activity in spleen (P=0.0076 unpaired t-test) and bone marrow 
(P=0.014 unpaired t-test) in CD150neg/HoxA9 HSCs was significantly higher than in 
the CD150pos/HoxA9 group. At time of euthanasia, the bone marrow consisted of 
about 84% of HoxA9-expressing cells and the spleen consisted of 33.5%. This 
extensive growth was not observed in the CD150pos/HoxA9 population, where the 
percentage of HoxA9-expressing cells was about 43% in bone marrow and 16% in 
spleen. The data suggest some correlation between the GFP expression levels in 
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blood and spleen (Pearson product-moment correlation coefficient of r=0.5148). By 
contrast, the GFP expression levels in blood and bone marrow were uncorrelated 
(r=0.0199).  
 
	  	     
Figure 11: GFP expression level in primary host mice (mean and SD). GFP is an indicator for 
HoxA9 activity. Both CD150neg/HoxA9 (n=10) and CD150pos/HoxA9 (n=6) mice showed low levels of 
GFP activity in the blood compared with bone marrow. The bone marrow of the CD150neg/HoxA9 mice 
consisted almost completely of cells positive for GFP. In the mice that received CD150pos/HoxA9, the 
bone marrow is composed of less than half of transduced cells. For both groups together a correlation 
analysis showed a Pearson product-moment correlation coefficient of r=0.5148 between the GFP 
activity in the blood and spleen. The correlation between GFP activity in the blood and bone marrow 
was negligible (r=0.0199). 
 
5.4. What blood marker changes can be seen? CD150neg/HoxA9 
primary host mice showed high numbers of Mac-1 positive cells in 
the blood 
Blood samples of injected mice were taken after 1, 3, and 5 months and were 
analyzed for B-cells (6B2), T-cells (31-11), and myeloid cells (Mac-1/8C5) using 
fluorescent antibodies, and the emissions were measured with a FACSCalibur 
cytometer. A total of 17 mice were injected with CD150neg/HoxA9 HSCs and 17 mice 
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received CD150pos/HoxA9 HSCs. Mice which showed at least 2% of GFP activity in 
the blood were considered for analysis. For the CD150neg/HoxA9 samples, a total of 
10 mice were analyzed. However, not every mouse had blood samples taken every 
month. There were different reasons for this, for example, because of a failure of the 
transplanted HSCs or because some mice were euthanized earlier than 5 months as 
they showed signs of leukemia. In addition, if the GFP levels were below 2% a 
reasonable evaluation was not possible. For CD150pos/HoxA9 HSCs a total of 6 mice 
were analyzed, and they had various numbers of samples for every month. The 
behaviors of CD150neg and CD150pos HSCs, which remained uninfected, have been 
published before (16, 19, 20, 53). The data for Figure 12 were acquired by gating for 
Ly45.1+ and GFP- cells. Therefore, the data represent HSCs sorted for CD150pos and 
CD150neg that have not been transduced with the HoxA9-overexpressing retrovirus 
vector. The non-infected CD150neg HSCs showed a noticeable bias towards 
differentiation into lymphoid cells. However, the blood samples of the HoxA9 
transduced CD150neg HSCs behaved differently. These cells showed high numbers 
of myeloid cells from the first month onward, whereas CD150pos HSCs transduced 
cells showed a similar behavior to non-infected CD150pos cells (Fig. 12 and Fig. 13). 
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Figure 12: Comparison of blood marker profiles of non-infected and transduced CD150pos and 
CD150neg HSCs. The blood samples were taken after 1, 3, and 5 months (horizontal axis). The non-
infected CD150neg HSCs (A) (n=5) showed a noticeable bias towards differentiation into lymphoid cells 
(31-11 and 6B2). However, HoxA9-transduced CD150neg HSCs (B) showed high numbers of myeloid 
cells  (8C5/Mac-1) starting with the first month (n=10). At the third and fifth month blood samples were 
drawn from 8 mice (n=8). 
Interestingly, CD150pos HoxA9-transduced cells (D) showed an almost similar behavior to non-infected 
CD150pos cells (C) (n=8). From CD150pos/HoxA9 mice (D), at the first monst blood was drawn from 6 
mice (n=6) at the third month from 5 mice (n=5) and at the fifth month from 4 mice (n=4). 
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Figure 13: Blood data at 3 months for 8C5/Mac-1. This graph highlights the data from Figure 12 for 
the blood marker 8C5/Mac-1. There was a significant difference (P<0.002) for the CD150neg HSCs 
between the transduced (n=8) vs. non-infected mice (n=5). However, there was no significant 
(P=0.3756) difference between the transduced (n=5) vs. non-infected CD150pos HSCs (n=8).  
  
5.5. Which roles do the bone marrow and spleen play in the 
leukemic behavior? CD150pos/HoxA9 primary host mice showed 
high numbers of Mac-1 cells in the bone marrow but not in the 
spleen 
The white blood cells were stained with monoclonal antibodies specific for Thy-1 (T-
lymphocytes), B220 (B-lymphocytes), and Gr-1 (granulocytes) and Mac-1 
(macrophages). For the CD150neg/HoxA9 and CD150pos/HoxA9 groups, 10 mice and 
six mice were analyzed, respectively. In bone marrow no significant difference 
between the 2 groups was detected. The HoxA9-expressing cells in the bone marrow 
were almost completely Mac-1 positive cells. In CD150neg/HoxA9 mice, the mean 
was 85%. In the CD150pos/HoxA9 group the mean was 77%. A non-parametric 
Mann-Whitney test had a P value of 0.0714 for this marker. A macroscopic picture of 
bone marrow cells is shown in Figure 15, and micrographs of the bone marrow are 
shown in Figure 21. 
In the spleen, significant differences between the CD150neg/HoxA9 and 
CD150pos/HoxA9 group were detectable. The CD150neg/HoxA9 consisted mostly of 
Mac-1 positive cells (mean 68.7%). An unpaired t-test showed a P value of 0.0365 
for this marker. In the spleens of the CD150neg/HoxA9 mice there were also cells 
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positive for 31-11 (20.8%) and  8C5 (15.4%). Again, the number for 6B2 positive cells 
was low at 7.8%. The HoxA9 positive cells of CD150pos/HoxA9 primary hosts showed 
a completely different picture; here the cells that were positive for 31-11 represented 
the largest group (46.1%). An unpaired t-test for this marker was not significant 
(P=0.0866). However, a non-parametric Mann-Whitney test showed significance with 
a value P=0.042. About 36.2% of the cells were positive for 6B2 (unpaired t-test 
P=0.0267). 
 
	  	    
Figure 14: Marker profile of bone marrow cells of primary host mice. CD150neg/HoxA9 mice 
(n=10)  and CD150pos/HoxA9 mice (n=6) showed a similar marker profile in the bone marrow with high 
numbers of Mac-1 positive cells.  
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Figure 15: Bone marrow cells of 2 primary host mice. One mouse received CD150neg/HoxA9 
HSCs and the other mouse received CD150pos/HoxA9 HSCs. The bone marrow was harvested, 
filtered, and then centrifuged. We can clearly see a difference in the color of these cell pellets. 
Although the marker profile is not different, the number of transduced cells is much higher in the bone 
marrow of the mice which were injected with CD150neg/HoxA9 HSCs, and the bone marrow consists 
almost completely of cells that have been transduced with HoxA9. The left test tube shows the typical 
white color of a leukemic bone marrow sample due to the enrichment of leucocytes characteristic of 
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Figure 16: Marker profile of spleen cells of primary host mice. The spleen cells of mice (n=10) 
which received CD150neg/HoxA9 HSCs showed a similar marker profile as in the bone marrow with a 
high number of Mac-1 positive cells. Spleen cells of CD150pos/HoxA9 HSCs mice (n=6) showed a 
completely different picture; here the cells that were positive for 31-11 were the largest group (46.1%), 
and about 36.2% of the cells were positive for 8C5. In contrast to the bone marrow, the number of 
Mac-1 positive (28.2%) cells is relatively low. 
 
5.6. Does the leukemic behavior stay consistent after serial 
transplantation of bone marrow cells into new host mice? 
For further investigations, 1 mouse of the primary CD150neg/HoxA9 group and 1 of 
the CD150pos/HoxA9 group were chosen at random, and the unseparated bone 
marrow was transplanted into 4 new host mice for each donor. For analysis and 
further serial transplantations these mice were all sacraficed between 2 and 2 1/2 
months after the start of the experiment. 
 
5.6.1. Secondary host mice showed an increased HoxA9 activity 
After euthanasia, the blood, spleen and bone marrow of the secondary host mice 
were analyzed using the same antibodies and procedures as in the primary hosts. In 
comparison to the GFP levels of the primary host mice, the levels of GFP+ cells had 
increased dramatically (Fig. 17). In particular, the number of GFP+ cells in the blood 
and spleen were increased. The bone marrow consisted almost exclusively of GFP+ 






























	   42	  
cells in both groups with no significant difference between the groups. The GFP 
activity in the spleen (P=0.0254 unpaired t-test) was significantly higher in the 
CD150neg/HoxA9 group. For the GFP levels in the blood a non-parametric Mann- 
Whitney test was not significant (P=0.0571). 
 
Figure 17: GFP expression level of primary and secondary host mice. GFP is an indicator for the 
HoxA9 activity. The data for the primary CD150pos/HoxA9 mice (n=6) and primary CD150neg/HoxA9 
mice (n=10) were already shown in Figure 11. Both CD150pos/HoxA9 (n=4) and CD150neg/HoxA9 
(n=4) showed an increase of GFP+ cells in all 3 examined tissues in the secondary host mice. The 
bone marrow of both groups consisted almost completely of GFP+ cells; in addition, the increase of 
GFP activity in blood and spleen compared to the primary group was striking.  
 
5.6.2. Secondary host mice showed high numbers of Mac-1 positive cells in 
bone marrow, spleen, and blood 
The analysis of the GFP+ cells in blood, spleen and bone marrow showed a dramatic 
increase of Mac-1 positive cells in the secondary host mice of the CD150pos/HoxA9 
group. In the secondary hosts no significant difference in the behavior of the 
transduced cells between the 2 groups was detected. Interestingly, the cells of the 
CD150neg/HoxA9 group began to show a loss of cell surface markers in spleen and 
bone marrow, which is indicated by a low percentage when all markers are added 
together. The beginning of the loss of markers and function, especially in the bone 
marrow, is also visible under the microscope (Fig. 21). 
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Figure 18: Marker profile in blood, spleen, and bone marrow cells of secondary host mice. The 
analysis of GFP+ cells showed a marked increase of Mac-1 positive cells in the secondary host mice 
of the CD150pos/HoxA9 (n=4) group. The secondary host mice of both groups now show a similar 
marker profile. Furthermore, the marker profile in the 3 tissues looks very similar with a high number of 
Mac-1 positive cells. The spleen and bone marrow cells of the CD150neg/HoxA9 (n=4) secondary host 
mice began to show a loss of cell surface markers with a decrease in Mac-1 positive cells.	  
	  
5.7. Spleen cells and bone marrow cells showed no difference in 
leukemic behavior when serially transplanted 
The primary host mice showed low numbers of HoxA9 activity (GFP+) in the blood 
compared to the high numbers in the bone marrow. This could suggest that extra-
medullary hematopoiesis takes place and keeps the organism alive. One possible 
place for this extra-medullary hematopoiesis is the spleen. To investigate this further, 
spleen cells and bone marrow cells from secondary host mice were transplanted into 
new hosts to see if different behavior could be observed. Two secondary host mice 
for both the CD150neg/HoxA9 group and for the CD150pos/HoxA9 group were used. 
Staining of bone marrow and spleen cells with mAb was performed. The remaining 
	   44	  
bone marrow cells were mixed and transplanted into the 2 new hosts for each group. 
In the same way, the remaining spleen cells were utilized. The main observation 
made was that the leukemia became more aggressive and resulted in the sudden 
death of all 4 mice within 1 month that received either bone marrow or spleen cells 
from the CD150neg/HoxA9. No obvious differences were visible between the mice that 
received bone marrow and the ones that received spleen cells. Because of the 
sudden death of those mice, no statistically valid staining was possible. The tertiary 
host mice of the CD150pos/HoxA9 group lived up to five months, and showed no 
difference between the mice which received spleen cells and the mice which 
received bone marrow cells.  
 
 
Figure 19: Time of survival of tertiary host mice. The mice were either euthanized when they 
showed signs of leukemic disease or they were found dead. All mice that received CD150neg/HoxA9 
cells (n=4) died within 1 month and the mean survival was 27,5 days. However, the mice that received 
CD150pos/HoxA9 cells (n=8) lived up to 5 months and the mean survival was 90 days. The Mantel-Cox 
test shows a significant difference between the two groups (P=0.0004) 
 
5.8. The number of transplanted cells had no impact on the 
leukemic behavior 
To demonstrate that the number of transplanted cells had no influence on the 
leukemic behavior, a serial dilution serial transplantation experiment was performed. 
Consequently, a primary host mouse of the CD150pos/HoxA9 and the 
CD150neg/HoxA9 group was euthanized, and unseparated whole bone marrow was 
 Survival of tertiary host mice
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serially transplanted into new hosts. Different amounts of bone marrow cells were 
serially transplanted 106, 3x106, and 107. The behavior in the blood was monitored 
with monoclonal antibodies specific for Thy-1 (T-lymphocytes), B220 (B- 
lymphocytes), and Gr-1 (granulocytes) and Mac-1 (macrophages) after 1 month. The 
primary hosts showed typical behavior as described in section 5.4. The blood of the 
primary CD150neg/HoxA9 host consisted almost exclusively of 8C5/Mac-1 positive 
cells (90%). The blood of the CD150pos/HoxA9 mouse was more diverse with 48.1% 
cells positive for 6B2 and only 23.4% positive for 8C5/Mac-1. The number of 31-11 
positive cells was 6.73% lower than in the CD150neg/HoxA9 host (20.5%). After serial 
transplantation of different numbers of unseparated whole bone marrow cells into 
new secondary host mice, the blood was evaluated after 1 month. A multivariate 
analysis of variance (MANOVA) showed that the number of transplanted cells had no 
influence on the leukemic behavior. The CD150neg/HoxA9 cells again consisted for 
the most part of 8C5/Mac-1 positive cells with all figures greater than 95%. In the 
new hosts of the CD150pos/HoxA9 the MANOVA also showed that the number of 
transplanted cells had no influence. Interestingly, the blood of the CD150pos/HoxA9 
mice shifted towards the myeloid lineage, with 8C5/Mac-1 positive cells being the 
biggest component (between 46% and 59%). This is consistent with the observations 
from 5.6.2. 
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Figure 20: Serial transplantation of different cell numbers. The left side represents the primary 
host of a CD150neg/HoxA9 (n=1) and a CD150pos/HoxA9 (n=1) mouse. The red arrow represents the 
transplantation of different numbers (106, 3x106, 107) of whole unseparated bone marrow cells from 
the primary host into new secondary hosts. Every bone marrow dilution was transplanted int 2 
secondary host mice (n=2 for every secondary host mice).  The right sides are the data from the first 
month blood sample of the secondary host mice. A MANOVA showed that the number of transplanted 
cells had no influence on the leukemic behavior. However, the CD150pos/HoxA9 cells shifted towards 
the myeloid lineage.  
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Figure 21: Photomicrographs of bone marrow cells. The micrographs are from different host mice 
(original magnification x200). Note that the difference in cell density could be due to the production 
process of the slides when the cells were diluted (See 4.15.) and does not represent the actual cell 
density. Picture A shows bone marrow from a primary host mouse that received CD150neg/HoxA9 
HSCs. Picture B shows bone marrow of a primary host mouse that received CD150pos/HoxA9 HSCs. 
Picture C shows bone marrow of a secondary host mouse. The cells appear to be uniform and to be 
myeloid blast cells, which is typical for the acute state of myeloid leukemia. Picture D shows bone 
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6. Discussion 
In these experiments the properties of several groups of HSCs that were modified in 
the same way were observed. Both CD150pos/HSCs and CD150neg/HSCs are a 
heterogenic mixture of various cell types. However, it can be assumed that the most 
prominent type of HSCs become transduced by the retroviral vector overexpressing 
HoxA9. This means that although CD150pos HSCs contain My-bi, Ly-bi and Bala 
HSCs, the My-bi are the ones who become transduced, and vice versa for the 
CD150neg, where the Ly-bi HSCs become transduced. Therefore, we observed the 
behavior of different stem cell mixtures, which become transduced with a HoxA9 
overexpressing retroviral vector. It can be assumed that the HoxA9 mutation not only 
alters the HSCs but also affects all daughter cells along the differentiation tree. 
	  
The laboratory of Christa Müller-Sieburg was the first to investigate the different 
leukemic behavior of My-bi and Ly-bi HSCs transduced with a retroviral vector 
overexpressing HoxA9. Rather than confirming the original hypothesis that only My-bi 
(CD150+) HSCs can give rise to myeloid leukemia, different leukemic behavior was 
seen in the 2 groups. Eventually, mice injected with transduced My-bi or Ly-bi 
(CD150-) developed myeloid leukemia. However, the mice that received Ly-bi HSCs 
showed an early and more aggressive onset of leukemia with an acute stage. The 
mice that received My-bi HSCs developed leukemia with a prolonged latency, and 
with no enlargement of spleens in the primary host.  
 
6.1. Mice injected with CD150neg/HoxA9 show early signs of 
leukemia 
The spleen weight was used as an indicator for the progression of leukemia. The 
enlarged spleens of primary host mice injected with CD150neg/HoxA9 HSCs indicate 
a rapid progressive leukemia, whereas in the CD150pos/HoxA9-injected mice normal 
spleen weights and no macroscopic signs of leukemia were detectable. This was 
consistent with previous data, where transduction of unseparated HSCs with HoxA9 
did not result in leukemia-specific phenotypes such as enlarged spleens (54). In line 
with these findings, we observed a similar phenotype within the CD150pos/HoxA9 
group. Notably, 70% of primary mice injected with CD150neg/HoxA9 HSCs exhibited 
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enlarged spleens and signs of leukemia. Thus, the results indicate that Ly-bi HSCs 
mediate an early onset of leukemia in primary mice. 
 
Strikingly, both groups of secondary host mice revealed a marked increase in spleen 
sizes. Although the mice were euthanized at an early age (2.5 months), their spleen 
size almost doubled compared to that of the primary hosts. This indicated a more 
aggressive progression of the leukemic disease. Nevertheless, the spleen sizes of 
the mice of the CD150neg/HoxA9 group are larger than the mice of the 
CD150pos/HoxA9. This fulminate progression of disease continued into the tertiary 
host mice, where all 4 recipients of the CD150neg/HoxA9 cells died within 1 month of 
transplantation. Tertiary host mice of CD150pos/HoxA9 HSCs survived up to 5 
months, but then also showed signs of leukemia. This means mice that received 
CD150pos/HoxA9 HSCs showed a survival benefit.   
A possible explanation for the different behavior is that My-bi possess a high self-
renewal capacity and a high repair rate for mutations, which protects them from 
“additional hits”; these are necessary to transform normal HSCs into leukemic stem 
cells when transduced with a retrovirus vector overexpressing HoxA9 (54). On the 
other hand, Ly-bi HSCs, which are short-lived, might not have these efficient repair 
mechanisms, more mutations could occur, and the cells could be transformed. This 
explanation would agree well with the observations of Thorsteinsdottir et al. (51) that 
HoxA9 overexpression alone is not enough to induce myeloid leukemia, and 
additional genetic events are necessary to trigger this leukemia. Beachy et al. 
suggest that isolated HoxA9 overexpression leads to a form of lymphoid leukemia 
(55). They established a transgenic mouse model to achieve the overexpression of 
HoxA9. However, the disease presentation of their mice was varied and some 
showed the typical signs of AML with enlarged spleens. From the long latency period 
of the disease onset, up to 18 months, they also concluded that other genetic factors 
were needed for disease development. The onset of leukemia in the secondary host 
mice of the CD150pos/HoxA9 group could be due to the additional stress of the serial 
transplantation, which could induce mutations and finally transform the My-bi HSCs 
into leukemic stem cells. A better understanding of the molecular processes which 
protect My-bi HSCs could lead to an improvement in leukemia research. Another 
explanation could be supplied by the studies of Thorsteinsdottir et al. (51). They 
showed that overexpression of HoxA9 leads to greatly enhanced HSC regeneration. 
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Similar results have been observed with the human fusion gene NUP98-HoxA9. 
Overexpression of this fusion gene leads to a greater proliferation rate of HSCs and a 
longer period of time over which HSCs can self-renew (56, 57). As My-bi HSCs are 
already characterized by high self-renewal rates and long periods of self-renewal, it is 
possible that they can cope better with the additional stress of the HoxA9 
overexpression. Ly-bi HSCs which have a low self-renewal capacity might be 
“overwhelmed” with the new conditions and more mutations might occur that 
transform Ly-bi HSCs into leukemic cells.  
One limitation to this finding could be due to the serial transplantation experimental 
procedure. Although the results were significant, the bone marrow from 1 primary 
mouse was serial transplanted into 4 new secondary host mice. This means that 
although every secondary host mice was analyzed separately, the cells all originated 
from 1 primary host mouse. 
 
6.2. HoxA9 slows down the repopulation of My-bi HSCs in the blood 
In the primary hosts the blood repopulation behavior showed some interesting 
differences. We observed an increase of GFP+ cells in the mice that received 
CD150neg/HoxA9 HSCs cells over 5 months. This could be a sign of a selection 
advantage and also of extensive growth, which is typical for leukemia cells. HoxA9 
seems to increase the rate of growth of Ly-bi HSCs, whereas the CD150pos/HoxA9 
primary host mice showed a decrease of GFP+ cells over 5 months. This is 
especially noteworthy as My-bi HSCs are rapidly cycling cells and an overall increase 
of donor-type cells was seen in these mice. This might suggest that HoxA9 can slow 
down the growth of My-bi HSCs.  
To further investigate the repopulation of CD150neg/HoxA9 HSCs and 
CD150pos/HoxA9 HSCs, a competitive in vitro experiment was designed (data not 
shown). Consequently, HoxA9 transduced HSCs were seeded together with F1 bone 
marrow cells in 1 cell flask. The hypothesis was that the CD150neg/HoxA9 would 
suppress the healthy bone marrow cells. However, this was not observed, and 
although CD150neg/HoxA9 HSCs possess a higher survival capacity in a competitive 
environment than CD150pos/HoxA9 HSCs, both groups showed a decline in the 
number of transduced cells (GFP+) over a period of 2 weeks. However, the decline in 
the number of CD150pos/HoxA9 cells was greater. There are multiple reasons why 
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the experiment did not show the predicted results. It is always difficult to grow 
leukemic cells in vitro and to find adequate culture conditions. Kroon et al. suggest 
that leukemic cells need 10% fetal calf serum and IL-3 to grow ex vivo (54). For these 
experiments, Dexter’s medium was used that did not contain IL-3. 
 
6.3. CD150neg/HoxA9 mice show the typical marker profile of AML 
The leukemic cells showed a noticeable bias towards the myeloid lineage. The 
CD150neg/HoxA9 primary host mice showed high levels of Mac-1 positive cells in the 
blood from the first month onward. Mac-1 positive cells also dominated in the bone 
marrow and spleen of these mice. These findings are similar to the results of Kroon 
et al. (54). They induced leukemia by transducing HSCs with a virus overexpressing 
HoxA9/Meis-1, and the leukemic cells were 100% Mac-1 positive. The same 
research team transduced mice with a retrovirus vector overexpressing only HoxA9. 
In these mice, after 4 and 8 weeks post translation, these researchers saw normal 
bone marrow and thymus cellularity and only mildly enlarged spleens, which is 
consistent with the findings in the CD150pos/HoxA9 primary host mice of these 
experiments (51). Another research group with similar results induced AML by 
overexpressing MLL-AF9 and also observed that almost all leukemic cells expressed 
Mac-1 or Gr-1 (58). However, Mac-1 positive cells seem to play an important role not 
only in mice but also in humans, where this kind of cell is observed in AML. The 
research group of Graf et al. (59) investigated the expression of Mac-1 (CD11b) in 
human AML. They found high expression of this marker especially in patients with 
the FAB subtypes M5, M4, and M1 and also in patients with an adverse cytogenetic 
risk. Therefore, they concluded that the high expression of Mac-1 is associated with a 
worse prognosis in humans with AML. The high levels of Mac-1 positive cells shown 
early by CD150neg/Hoxa9 primary host mice are further evidence for the more acute 
state of this type of leukemia. High levels of Mac-1 positive cells in the 
CD150pos/HoxA9 mice were only observed after serial transplantation into secondary 
host mice.  
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6.4. The spleen could be a place of extra-medullary hematopoiesis 
The blood from the primary hosts of both groups showed low levels of GFP/HoxA9 
activity. However, the GFP activity in the bone marrow was much higher. The 
difference between peripheral circulating blast cells and the blast levels in the bone 
marrow is not well understood. Amin et al. performed a monocentric study where 
they compared these 2 blast levels in patients with myelodysplastic syndrome (MDS), 
acute lymphocytic leukemia (ALL), or AML. They showed that in patients with MDS 
and ALL, higher peripheral blast cell levels were associated with a more aggressive 
disease and a shorter survival. In patients with AML this was not true, as the 
circulating blast levels seemed to have no clinical relevance. They hypothesized that 
adhesion molecules, chemokine, angiogenetic factors, and homing play a role in 
mobilizing blast cells in the bone marrow. However, they had no explanation why 
some AML patients have “massive infiltration of bone marrow by blasts but lack 
circulating blasts” (60). This lack of circulating blast cells, while the bone marrow is 
almost completely infiltrated, could be an indicator for extra-medullary hematopoiesis. 
When the bone marrow begins to fail, healthy hematopoiesis and also some parts of 
the leukemic hematopoiesis are relocated to organs like the spleen and liver to keep 
the organism alive. However, the origin of these hematopoietic precursor cells and 
the molecular mechanisms underlying their development in the spleen is uncertain. 
Hsieh et al. suggested that in chronic myeloproliferative disorders these cells 
originate from transformed bone marrow cells (61). In our experiment the correlation 
analysis suggests that the cells that are circulation in the blood correlate more with 
the cells in the spleen than in the bone marrow. Which suggests that the 
hematopoiesis in the bone marrow fails, and then the cells are not mobilized from the 
bone marrow and do not circulate in the blood. The spleen and probably other organs 
take over hematopoiesis and their cells circulate in the blood. The CD150neg/HoxA9 
HSCs mice showed higher levels of GFP+ cells in the bone marrow and spleen in 
primary hosts compared to the CD150pos/HoxA9 cells. From these results it can be 
assumed that CD150neg/HoxA9 cells grow extensively and suppress normal cells, 
until the bone marrow consists exclusively of HoxA9-transduced cells. This is typical 
for an acute stage of leukemia. In the secondary host mice, the main observation 
regarding the GFP levels is the markedly increased number of GFP+ cells in the 
blood and spleen, which indicates that the healthy extra-medullary hematopoiesis is 
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not sufficient or that it is dominated by leukemia cells. The organism fails to produce 
healthy cells, and we can observe the outcome to be fully developed leukemia. To 
investigate the behavior of extra-medullary hematopoiesis further, bone marrow and 
spleen cells from secondary host mice were transplanted into new host mice to 
observe their leukemic behavior. There was, however, no significant difference 
between mice that received spleen cells and mice that received bone marrow cells. 
This might be due to our use of secondary host mice. In this population the 
percentage of HoxA9 expressing cells was already very high in both tissues, and 
both tissues showed a similar marker profile with high numbers of Mac-1 positive 
cells, which is typical for AML. Transplantation of spleen and bone marrow from 
primary host mice, when the extra-medullary hematopoiesis is still intact, might 
reveal different results. 
 
6.5. Through serial transplantation leukemia becomes more 
aggressive 
Beginning in the secondary, and continuing in the tertiary hosts, we saw a loss of 
markers in the CD150neg/HoxA9 mice. This is another indicator that the AML is more 
aggressive and progresses faster in these mice. Loss or shifts of cell surface markers 
are widely observed in cases of leukemia. Tomová et al. saw a frequent loss of CD34 
and CD10 in their patients with ALL. They also observed a loss of CD1 and CD2 in 
patients with T-ALL (62). Yoo et al. even suggested that the expression of CD7 
should be included in the diagnosis of natural killer-cell neoplasms, because they 
observed a frequent loss of CD7 in patients with aggressive natural killer-cell 
leukemia (63). These observations also led to the following conclusion - that not only 
was the potential to initiate leukemia maintained upon serial transplantation, but also 
that the progression of the leukemic disease became more and more aggressive 
from host to host. Serial transplantations of leukemia cells have been performed 
before. The one that is most similar to these experiments was performed by Kroon et 
al. (64). They used the fusion gene NUP98-HoxA9 to trigger leukemia, and they also 
observed that the outbreak of leukemia was much faster in the secondary host. In 
addition, this led them to the conclusion that NUP98-HoxA9 alone was not sufficient 
to induce leukemia, and that additional genetic events were required. Schulze  et al. 
(65) induced AML by overexpressing MLL-AF9. These researchers were also able to 
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show that the potential to initiate leukemia was maintained following serial 
transplantation. However, they did not see an increase of aggressiveness in the 
leukemia. These different findings are probably due to the different genes that were 
overexpressed. Overexpression of MLL-AF9 alone is already sufficient to induce 
AML. For our experiments HoxA9 was used, which is not capable alone of causing 
AML in HSCs. Use of serial transplantation puts additional stress on the cells and 
more mutations occur, which can then lead to leukemia. Other research groups have 
used different species or studied different types of leukemia (66-68). However, all the 
work had a common feature in that there was no observation of an increase in the 
aggressiveness of the disease. A serial dilution experiment was performed to rule out 
the possibility that the number of transplanted cells has an effect on the type of 
leukemic behavior. The analysis showed that the number of transplanted cells had no 
influence on the leukemic behavior. Although the experiment showed a valid result 
statistically, it was only performed once, which could be a point of limitation. 
 
6.6. Limitations 
One of the limitations was transplant failure respectively the decrease of HoxA9 
transduced cells in the blood, spleen and bone marrow. Out of the 17 primary host 
mice that received CD150pos/HoxA9 HSCs, 9 mice showed a transplant failure with 
not enough transduced/GFP+ cells at the time of sacrifice in any tissue. From the 17 
primary host mice that were injected with CD150neg/HoxA9 HSCs, only 3 mice 
showed a transplant failure. One might assume that this could be simply due to 
problems with venipuncture injection. However, this can be ruled out by the fact that 
the mice were lethally irradiated and would not have survived without a successful 
injection of cells. The data of all 17 mice for each group is shown in Figure 8. This 
figure shows the decrease of HoxA9 expressing cells in the primary host mice that 
received CD150pos/HoxA9 HSCs. This is a main finding of this thesis. However, this 
means that after 5 months there were not enough HoxA9 expressings cells left for a 
reasonable analysis. To explain why HoxA9 slows down the growth of these cells, 
further research is needed. Four primary host mice that were injected with 
CD150neg/HoxA9 HSCs, died suddenly (e.g on a weekend) and were found dead, so 
that an analysis of bone marrow and spleen was not possible. 
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The lack of circulating GFP+ cells in the blood was another challenge. Even when 
the bone marrow showed a massive infiltration of transduced cells (above 80%), the 
number of circulating transduced cells in the blood stream was often below 10%. 
Only mice that had more than 2% of transduced cells in all 3 tissues (bone marrow, 
spleen, and blood) were included for analysis. This excluded 2 primary mice from 
analysis that received CD150pos/HoxA9 HSCs. Although the 2 mice had sufficient 
transduced cells in their bone marrow (41% and 28.5%), the number of GFP 
cexpressing cells in their spleens and blood was below 2%. This could be a 
compensation by the organism to keep it alive or simple due to the effect that HoxA9 
slows down the growth of My-bi cells. Nevertheless, the low numbers of transduced 
cells make a reasonable analysis impossible.  As mentioned in 6.4., the difference 
between the infiltration of bone marrow and circulating blast cells is not well 
understood in AML, and further research of adhesion molecules, chemokine, 
angiogenetic factors, and homing is needed (60). 
Only about 1 of every 10,000 to 100,000 bone marrow cells is an HSC - this makes 
HSCs very rare cells in mammalian bone marrow (69, 70). For these experiments, 
highly purified HSCs that were sorted with antibodies and a FACSaria cytometer 
were used. The marker profile of c-Kit+; Sca-1+; lineage markers negative (Lin-); 
CD34- gives one of the highest yields when sorting for HSCs. It has been shown that 
small numbers of these cells are enough for the long-term repopulation of an 
irradiated host (13, 71). However, these populations are still not completely pure, and 
it is possible that instead of an HSC, the target for the leukemic transformation is a 
more committed progenitor. This could be a restricted myeloid progenitor or a short-
lived multi-potent progenitor. A great effort has been made to improve the sorting 
protocols, and many different protocols and cell surface markers have been used to 
identify and isolate HSCs from mouse bone marrow. However, a consensus 
regarding which markers are consistently expressed on HSCs has not yet been 
reached (72). Recently, a new way to isolate HSCs was introduced (72). Bone 
marrow cells are stained with nontoxic dye and transplanted into new host animals. 
Some of the injected cells migrate to the bone marrow of the recipients within 48 
hours. When these cells are harvested and serially transplanted into a new host, the 
cells are highly enriched for stem cells.  
Another way to investigate if stem cells are the target of leukemic transformation is to 
improve the virus used for transfection. The retrovirus vector used for these 
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experiments was not selective, and therefore it could transduce all cells it came in 
contact with. To advance the method, it would be necessary to develop a retrovirus 
vector that only transduces HSCs. Our laboratory has been working on improving the 
plasmid construct by using promoter genes only expressed in HSCs, but the new 
plasmid was not completed in time to be used in these experiments. Improving the 
purity of the sorted HSC population and developing a retrovirus that only transduces 
HSCs could help to solve the question of which cells are the target cells of leukemic 
transformation.  
 
6.7. Prospects – My-bi HSCs might improve HSCs transplantation 
The results show that mouse HSCs sorted for CD150pos are more resistant to 
leukemia caused by an overexpression of HoxA9 than HSCs sorted for CD150neg. As 
HoxA9 is expressed in about 50% of patients with AML, these findings could have an 
enormous impact on the clinical treatment for patients with leukemia. One of the 
cornerstones of leukemic therapy in humans is the transplantation of HSCs. To 
achieve this, all remaining cells in the bone marrow of a patient are killed by 
chemotherapy, radiotherapy, or other modalities (e.g. tyrosine kinase inhibitors [TKIs] 
and antibodies) to reach a state of remission. Then the HSCs are transplanted, either 
from the patient (autologous), or from a healthy donor (allogeneic). This therapy is 
often the treatment of last resort, as it results in high failure rates. Depending on the 
type of leukemia and the time point of the treatment, the relapse rates are 20% to 
80% for allogeneic stem cell transplantation (73). The management of failure of 
transplantation is a major challenge, and the therapies range from simple support 
and palliation to second attempts to cure with second transplants. At present, 
unsorted HSCs are used for transplantation to cure patients with various forms of 
leukemia. However, these experiments could show that mice injected with 
CD150pos/HoxA9 HSCs survive significantly longer than mice injected with 
CD150neg/HoxA9 HSCs. A sorting of the HSCs which are transplanted into patients 
for CD150 could be a major benefit for patients. Nevertheless, at this early stage of 
research, all prospects are mainly speculative. 
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6.8. Conclusion 
Rather than confirming the hypothesis that only one HSC compartment is responsible 
for inducing AML, the results showed convincingly that mice injected with 
CD150neg/HoxA9 HSCs showed an early onset of AML, a more rapid progression of 
the disease, and eventually a shorter lifespan. Conversely, mice that received 
CD150pos/HoxA9 HSCs showed signs of AML only after serial transplantation into 
secondary host mice. Furthermore, the experiments showed that the number of 
transplanted cells had no effect of the type of leukemia. There was also no difference 
in the leukemic behavior whether it was spleen cells or bone marrow cells that were 
serially transplanted. This suggests that the clonal heterogeneity in the normal blood 
system is causative for heterogeneous manifestations of acute myeloid leukemia 
derived from the same initial transformation. The experiments presented in this thesis 
suggest that, in fact, disease pathways diverge and are manifest in typical clinical 
identifiers such as enlarged spleens. These findings could have important 
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8. Appendix 
8.1 Eidesstattliche Versicherung  
  
„Ich, Michael Ziller, versichere an Eides statt durch meine eigenhändige Unterschrift, 
dass ich die vorgelegte Dissertation mit dem Thema: „Overexpression of HoxA9 in 
CD150- hematopoietic stem cells leads to rapid progression of acute myeloid 
leukemia“ selbstständig und ohne nicht offengelegte Hilfe Dritter verfasst und keine 
anderen als die angegebenen Quellen und Hilfsmittel genutzt habe.  
Alle Stellen, die wörtlich oder dem Sinne nach auf Publikationen oder Vorträgen 
anderer Autoren beruhen, sind als solche in korrekter Zitierung (siehe „Uniform 
Requirements for Manuscripts (URM)“ des ICMJE -www.icmje.org) kenntlich 
gemacht. Die Abschnitte zu Methodik (insbesondere praktische Arbeiten, 
Laborbestimmungen, statistische Aufarbeitung) und Resultaten (insbesondere 
Abbildungen, Graphiken und Tabellen) entsprechen den URM (s.o) und werden von 
mir verantwortet.  
Meine Anteile an etwaigen Publikationen zu dieser Dissertation entsprechen denen, 
die in der untenstehenden gemeinsamen Erklärung mit dem/der Betreuer/in, 
angegeben sind. Sämtliche Publikationen, die aus dieser Dissertation 
hervorgegangen sind und bei denen ich Autor bin, entsprechen den URM (s.o) und 
werden von mir verantwortet. 
 
Die Bedeutung dieser eidesstattlichen Versicherung und die strafrechtlichen Folgen 
einer unwahren eidesstattlichen Versicherung (§156,161 des Strafgesetzbuches) 
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8.2 Resume 
Mein Lebenslauf wird aus wird aus datenschutzrechtlichen Gründen in der 
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